MedStar Washington Hospital Centre, Washington, DC and Georgetown University School of Medicine, Washington, DC, USA.
Saint Luke's Mid America Heart Institute, Kansas City, MO, USA and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Eur J Vasc Endovasc Surg. 2024 Apr;67(4):644-652. doi: 10.1016/j.ejvs.2023.11.017. Epub 2023 Nov 21.
To compare thrombus removal and residual venous symptoms and signs of disease following interventional treatment of iliofemoral deep vein thrombosis (DVT) with mechanical thrombectomy (MT) and pharmacomechanical catheter directed thrombolysis (PCDT).
Retrospective cohort analysis of propensity score matched subgroups from the multicentre prospective MT ClotTriever Outcomes registry and the PCDT arm of the randomised Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter Directed Thrombolysis trial. Patients with bilateral DVT, symptom duration greater than four weeks, isolated femoral-popliteal disease, or incomplete case data were excluded. Patients with iliofemoral DVT were propensity score matched (1:1) on 10 baseline covariables, including race, sex, age, body mass index, leg treated, prior thromboembolism, Marder score, symptom duration, provoked deep vein thrombosis status, and Villalta score. Reduction in post-procedure thrombus burden (i.e., Marder scores), assessment of venous symptoms and signs (i.e., Villalta scores) at 12 months, and healthcare resource utilisation were compared between subgroups.
Propensity score matching resulted in 130 patient pairs with no significant differences in baseline characteristics between the MT and PCDT groups. MT was associated with a greater reduction in Marder scores (91.0% vs. 67.7%, p < .001), and a greater proportion of patients at 12 months with no post-thrombotic syndrome (83.1% vs. 63.6%, p = .007) compared with matched patients receiving PCDT. No differences in rates of adjunctive stenting or venoplasty were identified (p = .27). Higher rates of single session treatment were seen with MT (97.7% vs. 26.9%, p < .001), which also showed shorter mean post-procedure hospital stays (1.81 vs. 3.46 overnights, p < .001), and less post-procedure intensive care unit utilisation (2.3% vs. 52.8%, p < .001).
Compared with PCDT, MT was associated with greater peri-procedural thrombus reduction, more efficient post-procedure care, and improved symptoms and signs of iliofemoral vein disease at 12 months.
比较介入治疗髂股深静脉血栓形成(DVT)时机械血栓切除术(MT)与药物机械导管定向溶栓(PCDT)的血栓清除率和残留静脉症状体征。
回顾性分析多中心前瞻性 MT ClotTriever Outcomes 注册研究和随机急性静脉血栓形成的 PCDT 臂:血栓切除联合辅助导管定向溶栓试验的倾向评分匹配亚组。排除双侧 DVT、症状持续时间超过 4 周、孤立的股腘静脉疾病或不完整的病例数据。对髂股 DVT 患者进行倾向评分匹配(1:1),匹配 10 个基线协变量,包括种族、性别、年龄、体重指数、治疗肢体、既往血栓栓塞、Marder 评分、症状持续时间、诱发深静脉血栓形成状态和 Villalta 评分。比较亚组之间术后血栓负荷(即 Marder 评分)的降低、12 个月时静脉症状和体征(即 Villalta 评分)的评估以及医疗保健资源的利用情况。
倾向评分匹配后,MT 组和 PCDT 组各有 130 对患者,两组患者的基线特征无显著差异。MT 组 Marder 评分降低更显著(91.0%比 67.7%,p<0.001),12 个月时无 post-thrombotic 综合征的患者比例更高(83.1%比 63.6%,p=0.007)。与接受 PCDT 的匹配患者相比,两组间辅助支架或血管成形术的使用率无差异(p=0.27)。MT 组单次治疗率更高(97.7%比 26.9%,p<0.001),术后平均住院时间更短(1.81 比 3.46 个晚上,p<0.001),术后 ICU 使用率更低(2.3%比 52.8%,p<0.001)。
与 PCDT 相比,MT 可在围手术期内更有效地清除血栓,改善术后症状体征,提高髂股静脉疾病的治疗效果。